Posted by Michael Wonder on 18 Oct 2022
AvroBio granted ILAP designation from UK MHRA for first in class gene therapy for Gaucher disease
18 October 2022 - ILAP intended to accelerate regulatory review process and facilitate patient access in UK for seriously debilitating and life-threatening diseases.
AvroBio today announced that the UK MHRA has granted an innovation passport under the innovative licensing and access pathway to investigational AVR-RD-02, a first in class gene therapy that uses patients’ own haematopoietic stem cells to treat Gaucher disease, a rare lysosomal disorder that can lead multi-organ pathology, clinical morbidity and early mortality.
